<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Scimitar Equity Blog &#187; Biotechnology</title>
	<atom:link href="http://www.scimitarequity.com/blog/category/biotechnology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.scimitarequity.com/blog</link>
	<description>Timely, Intelligent Analysis</description>
	<lastBuildDate>Fri, 03 Sep 2010 14:21:11 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Vatican Calls Synthetic Cell Creation &#8211; &#8220;Interesting”</title>
		<link>http://www.scimitarequity.com/blog/2010/05/24/vatican-calls-synthetic-cell-creation-interesting%e2%80%9d/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/24/vatican-calls-synthetic-cell-creation-interesting%e2%80%9d/#comments</comments>
		<pubDate>Mon, 24 May 2010 12:47:07 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cell Therapy]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[embryonic stem cells]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[J. Craig Venter]]></category>
		<category><![CDATA[J. Craig Venter Institute]]></category>
		<category><![CDATA[NASDAQ:NBS]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[stem cell technology]]></category>
		<category><![CDATA[Vatican]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=4756</guid>
		<description><![CDATA[The Vatican praised scientists, who had created the world&#8217;s first synthetic cell, calling it an &#8220;interesting result&#8221; that could help cure disease.  The Vatican newspaper L&#8217;Osservatore Romano called it &#8220;important research&#8221; and &#8220;the work of high-quality genetic engineering.&#8221;  But it said the scientists who created the cell had not created life,  just &#8220;replaced one of its [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/24/vatican-calls-synthetic-cell-creation-interesting%e2%80%9d/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First Synthetic Life Form, Medical Science Might Be Changed Forever</title>
		<link>http://www.scimitarequity.com/blog/2010/05/23/first-synthetic-life-form-medical-science-might-be-changed-forever/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/23/first-synthetic-life-form-medical-science-might-be-changed-forever/#comments</comments>
		<pubDate>Sun, 23 May 2010 19:25:26 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cell Therapy]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[J. Craig Venter]]></category>
		<category><![CDATA[J. Craig Venter Institute]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[Vatican]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=4765</guid>
		<description><![CDATA[A team of scientists at the J. Craig Venter Institute announced that they have successfully created a living organism with a completely synthetic genome.
After almost 15 years of work and $40 M, a team of scientists at the J. Craig Venter Institute have succeeded in creating the first living organism with a completely synthetic genome. [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/23/first-synthetic-life-form-medical-science-might-be-changed-forever/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Massing at the Starting Line for the $1B Program Tax/Grant Program</title>
		<link>http://www.scimitarequity.com/blog/2010/05/22/massing-at-the-starting-line-for-the-1b-program-taxgrant-program/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/22/massing-at-the-starting-line-for-the-1b-program-taxgrant-program/#comments</comments>
		<pubDate>Sat, 22 May 2010 13:07:01 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Diagnostic and Device Sector Initiatives]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=4641</guid>
		<description><![CDATA[Small life-sciences companies in the US will get funds in the form of tax credits or as a grant covering 50% of project development costs (for 2009 and 2010) for companies with fewer than 250 workers. The plan, part of the US healthcare overhaul approved in March, is expected to be open to hundreds of biotech, medical [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/22/massing-at-the-starting-line-for-the-1b-program-taxgrant-program/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Three (3) Stem Cell Lines Now on Hold by the NIH</title>
		<link>http://www.scimitarequity.com/blog/2010/05/05/three-3-stem-cell-lines-now-on-hold-by-the-nih/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/05/three-3-stem-cell-lines-now-on-hold-by-the-nih/#comments</comments>
		<pubDate>Wed, 05 May 2010 13:15:58 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cell Therapy]]></category>
		<category><![CDATA[Sector Analysis]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[Children's Hospital]]></category>
		<category><![CDATA[Dana Farber Cancer Institute]]></category>
		<category><![CDATA[Equity Research]]></category>
		<category><![CDATA[George Q. Daley]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Independent Equity Research BING]]></category>
		<category><![CDATA[Independent Equity Research Biotechnology]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[PhD]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[StemCells]]></category>
		<category><![CDATA[Three (3) human embryonic stem cell lines once eligible for federal funding are "on hold"]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=4008</guid>
		<description><![CDATA[
Three (3) human embryonic stem cell lines once eligible (5/4/10) for federal funding are &#8220;on hold&#8221; until further notice because they were derived from embryos that were too early. &#8220;These lines were derived from early embryos &#8212; those consisting of 6, 8, or 16 cells and thus formally did not fit the official definition of [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/05/three-3-stem-cell-lines-now-on-hold-by-the-nih/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NIH Study Confirms Location of Stem Cells Near Cartilage</title>
		<link>http://www.scimitarequity.com/blog/2010/05/04/nih-study-confirms-location-of-stem-cells-near-cartilage/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/04/nih-study-confirms-location-of-stem-cells-near-cartilage/#comments</comments>
		<pubDate>Tue, 04 May 2010 12:57:35 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Sector Analysis]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[bone-generating stem cells]]></category>
		<category><![CDATA[Equity Research]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Independent Equity Research BING]]></category>
		<category><![CDATA[Independent Equity Research Biotechnology]]></category>
		<category><![CDATA[Independent Equity Research blogging from wayland]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Proceedings of the National Academy of Sciences]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[StemCells]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=3575</guid>
		<description><![CDATA[NIH Researchers have discovered bone-generating stem cells in the spine, at the end of the shins and in cartilage-rich areas of other bones. They also identified factors that control the growth of these stem cells, according to a report published (4/26/10) in the Proceedings of the National Academy of Sciences. The potential for this market [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/04/nih-study-confirms-location-of-stem-cells-near-cartilage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent on Human Embryonic Stem Cells Rejected after Appeal</title>
		<link>http://www.scimitarequity.com/blog/2010/05/03/patent-on-human-embryonic-stem-cells-rejected-after-appeal/</link>
		<comments>http://www.scimitarequity.com/blog/2010/05/03/patent-on-human-embryonic-stem-cells-rejected-after-appeal/#comments</comments>
		<pubDate>Mon, 03 May 2010 16:10:49 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[Consumer Watchdog]]></category>
		<category><![CDATA[Equity Research]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corp]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[human embryonic stem cells]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[US Patent and Trademark Office]]></category>
		<category><![CDATA[WARF]]></category>
		<category><![CDATA[Wisconsin Alumni Research Foundation]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=3894</guid>
		<description><![CDATA[The US Patent and Trademark Office (USPTO) rejected (4/28/10) a controversial patent on human embryonic stem cells held by the Wisconsin Alumni Research Foundation (WARF). &#8220;This is a major victory for unfettered scientific research that could lead to &#8230; cures for some of the most debilitating diseases,&#8221; said John M. Simpson, Consumer Watchdog&#8217;s (CW) Stem Cell [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/05/03/patent-on-human-embryonic-stem-cells-rejected-after-appeal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Athersys&#8217; (NASDAQ: ATHX) Investor/R&amp;D Day</title>
		<link>http://www.scimitarequity.com/blog/2010/04/22/athersys-nasdaq-athx-investorrd-day/</link>
		<comments>http://www.scimitarequity.com/blog/2010/04/22/athersys-nasdaq-athx-investorrd-day/#comments</comments>
		<pubDate>Thu, 22 Apr 2010 12:39:34 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[allogeneic stem cell therapy]]></category>
		<category><![CDATA[ATHERSYS]]></category>
		<category><![CDATA[Athersys has forged strategic partnerships with Pfizer]]></category>
		<category><![CDATA[ATHX]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[Cardiovascular Disease]]></category>
		<category><![CDATA[Equity Research]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Immune System Modulation]]></category>
		<category><![CDATA[Independent Equity Research acute myocardial infarction (AMI)]]></category>
		<category><![CDATA[Independent Equity Research BING]]></category>
		<category><![CDATA[NASDAQ: ATHX]]></category>
		<category><![CDATA[neurological disease]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Ph I clinical trial of MultiStem®]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[small molecule programs]]></category>
		<category><![CDATA[Stem Cell Technology BING]]></category>
		<category><![CDATA[StemCells]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=3308</guid>
		<description><![CDATA[Athersys, Inc. (NASDAQ: ATHX) will host its 2nd Annual Investor/R&#38;D Day which will be held at the Intercontinental Hotel on Friday, 5/14/10 in New York City. The meeting will begin at 8:30 to 11:30 am ET.  The investor day will feature a series of presentations which will provide an overview of relevant clinical areas and [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/04/22/athersys-nasdaq-athx-investorrd-day/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New NIH Common Fund</title>
		<link>http://www.scimitarequity.com/blog/2010/02/27/new-nih-common-fund/</link>
		<comments>http://www.scimitarequity.com/blog/2010/02/27/new-nih-common-fund/#comments</comments>
		<pubDate>Sat, 27 Feb 2010 17:01:39 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Sector Analysis]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[7 scientific initiatives]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[Global Health Program]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry mccusker]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[http://commonfund.nih.gov]]></category>
		<category><![CDATA[Knockout Mouse Phenotyping Program]]></category>
		<category><![CDATA[Library of Integrated Network-based Cellular Signatures Program]]></category>
		<category><![CDATA[LINCS]]></category>
		<category><![CDATA[National Institutes of Health]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[NIH Common Fund]]></category>
		<category><![CDATA[NIH Induced Pluripotent Stem (iPS) Cell Center]]></category>
		<category><![CDATA[Protein Capture Reagents Program]]></category>
		<category><![CDATA[Regulatory Science Program]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Research BING]]></category>
		<category><![CDATA[Science of Behavior Change Program]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=2726</guid>
		<description><![CDATA[ Programs to create a new center for the study of stem cells and to increase capacity to deal with global health issues were among 7 scientific initiatives announced 2/25/10 by NIH Director Francis S. Collins, MD, PhD. The 7 research programs are supported through the NIH Common Fund, which encourages collaborative research programs across the NIH [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/02/27/new-nih-common-fund/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Q4/09 Results, Osiris Therapeutics (OSIR)</title>
		<link>http://www.scimitarequity.com/blog/2010/02/25/q409-results-osiris-therapeutics-osir/</link>
		<comments>http://www.scimitarequity.com/blog/2010/02/25/q409-results-osiris-therapeutics-osir/#comments</comments>
		<pubDate>Thu, 25 Feb 2010 14:42:59 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Sector Analysis]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[allogeneic bone marrow transplantation]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[Chondrogen]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[google]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[GvHD]]></category>
		<category><![CDATA[henry mccusker]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Journal of the American College of Cardiology]]></category>
		<category><![CDATA[Juvenile Diabetes Research Foundation (JDRF)]]></category>
		<category><![CDATA[Mesenchymal stem cells]]></category>
		<category><![CDATA[MSC's]]></category>
		<category><![CDATA[NASDAQ: OSIR]]></category>
		<category><![CDATA[National Institutes of Health]]></category>
		<category><![CDATA[new Biosurgery division]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Prochymal]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Stem Cell Technology a treatment of osteoarthritis and the reduction of pain in the knee.]]></category>
		<category><![CDATA[Yahoo]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=2638</guid>
		<description><![CDATA[ Osiris Therapeutics is a stem cell therapeutic company focused on developing products in the inflammatory, orthopedic and cardiovascular areas.  OSIR’s  Q4/09 results reported achievement and data showing Prochymal achieved a 63% response rate when used as a rescue agent in children with end-stage GvHD with significant improvement in response rates over standard of care [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/02/25/q409-results-osiris-therapeutics-osir/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Updating, BrainStorm Cell Therapeutics (OTCBB: BCLI)</title>
		<link>http://www.scimitarequity.com/blog/2010/02/24/updating-brainstorm-cell-therapeutics-otcbb-bcli/</link>
		<comments>http://www.scimitarequity.com/blog/2010/02/24/updating-brainstorm-cell-therapeutics-otcbb-bcli/#comments</comments>
		<pubDate>Wed, 24 Feb 2010 09:17:35 +0000</pubDate>
		<dc:creator>Henry McCusker</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Independent Equity Research]]></category>
		<category><![CDATA[Sector Analysis]]></category>
		<category><![CDATA[Stem Cell Technology]]></category>
		<category><![CDATA[financings]]></category>
		<category><![CDATA[Amyotrophic Lateral Sclerosis (ALS)]]></category>
		<category><![CDATA[BING]]></category>
		<category><![CDATA[BLCI.OB]]></category>
		<category><![CDATA[blogging from wayland]]></category>
		<category><![CDATA[bone marrow cells]]></category>
		<category><![CDATA[BrainStorm]]></category>
		<category><![CDATA[BrainStorm Cell Therapeutics]]></category>
		<category><![CDATA[Google finance]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[henry w mccusker]]></category>
		<category><![CDATA[Lou Gehrig’s Disease]]></category>
		<category><![CDATA[neurotrophic-factor secreting cells (glial cells)]]></category>
		<category><![CDATA[Ramot at Tel Aviv University]]></category>
		<category><![CDATA[Scimitar Equity]]></category>
		<category><![CDATA[Scimitar Equity blog]]></category>
		<category><![CDATA[stem cell sector]]></category>
		<category><![CDATA[stem cell technology]]></category>
		<category><![CDATA[Stem Cell Technology adult stem cells]]></category>
		<category><![CDATA[Tel-Aviv University]]></category>
		<category><![CDATA[yahoo finance]]></category>

		<guid isPermaLink="false">http://www.scimitarequity.com/blog/?p=2527</guid>
		<description><![CDATA[ BCLI.OB announced that it has entered into agreements with 3 investors with each investing $500 K for a total of investment of $1.5 M with issuance to each of 3 investors,  2 M shares of stock based on the 30 day average share price as of 2/11/10 of $0.25 per share and 1 M [...]]]></description>
		<wfw:commentRss>http://www.scimitarequity.com/blog/2010/02/24/updating-brainstorm-cell-therapeutics-otcbb-bcli/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
